Purpose
CDC's Influenza Division is offering an Influenza and SARS-CoV-2 Molecular Diagnostic Performance Evaluation Panel to qualified public health labs during the month of April 2026.
Request Form
This panel consists of nine specimens requiring identification of influenza type (A/B), SARS-CoV-2 and characterization of subtype and/or genotype to evaluate the performance of the CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel kits for Influenza A/B typing (VER 2) (FluIVD03-9), Influenza A subtyping ( VER4) (FluIVD03-12), Influenza A/H5 subtyping (VER 4) (FluIVD03-11) and Influenza A/H7 (Eurasian Lineage) subtyping (FluEUA-01) and CDC Influenza A/B SARS-CoV-2 Multiplex assay panel FluSC2PPB-EUA for oligos, and FluSC2PC-EUA for control materials. The purpose of this exercise is to assist public health laboratories in evaluating performance of laboratories using molecular diagnostic methods for influenza and SARS-CoV-2 detection and characterization, and to assist APHL and CDC in understanding performance of the CDC Flu rRT-PCR Dx Panel and CDC FluSC2 EUA reagent kits in US public health laboratories. This exercise is not a CLIA or CAP certified proficiency testing program. Although participation in this exercise is encouraged, it is strictly voluntary.
Public health laboratories interested in participating in this performance evaluation exercise are requested to submit the enrollment from April 20, 2026, to May 20, 2026.
If you have any questions, please direct them to FluPEP@cdc.gov.
All fields are required unless otherwise indicated.